Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 96

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 96
---
 in 2026.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  35

NOTE 17—SEGMENT INFORMATION

The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain therapies. The Company is managed by a single management team, and consistent with its organizational structure, the Chief Executive Officer—who is the Company’s chief operating decision maker, or CODM—manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one operating segment and one reportable segment to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.The key measure of the Company is GAAP net income. The CODM uses this measure to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.There are significant expense categories and amounts that are regularly provided to the CODM. These expense categories differ from what is disclosed in the Company’s financial results. The table below reconciles the significant expense categories provided to the CODM to the Company’s expenses as disclosed under GAAP (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Revenues$179,516 $168,573 $529,538 $513,713 Less:Adjusted cost of goods sold32,772 37,355 98,025 126,646 Adjusted research and development22,489 17,310 70,276 52,158 Adjusted selling and marketing58,471 43,191 165,006 121,673 Adjusted general and administrative23,180 21,831 70,020 66,097 Goodwill impairment— 163,243 — 163,243 Stock-based compensation13,978 13,230 44,003 38,905 Amortization of acquired intangible assets14,322 14,322 42,966 42,966 Changes in the fair value of contingent consideration625 (3,244)(2,407)(5,541)Legal settlement— — 7,000 — Legal judgment(23,148)— (23,148)— Impairment of acquired IPR&D25,866 — 25,866 — Other4,599 862 15,080 5,641 Total operating